## CITATION REPORT List of articles citing

The Assessment of Convalescent Plasma Efficacy against COVID-19

DOI: 10.1016/j.medj.2020.11.002 Med, 2020, 1, 66-77.

Source: https://exaly.com/paper-pdf/75747271/citation-report.pdf

Version: 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
16	Convalescent Plasma Use in the United States was inversely correlated with COVID-19 Mortality: Did Plasma Hesitancy cost lives?. <b>2021</b> ,		7
15	The Principles of Antibody Therapy for Infectious Diseases with Relevance for COVID-19. <i>MBio</i> , <b>2021</b> , 12,	7.8	26
14	Convalescent Plasma Therapy for COVID-19: A Graphical Mosaic of the Worldwide Evidence. <i>Frontiers in Medicine</i> , <b>2021</b> , 8, 684151	4.9	17
13	Convalescent plasma use in the USA was inversely correlated with COVID-19 mortality. <i>ELife</i> , <b>2021</b> , 10,	8.9	9
12	Rapid and Flexible Platform To Assess Anti-SARS-CoV-2 Antibody Neutralization and Spike Protein-Specific Antivirals. <i>MSphere</i> , <b>2021</b> , 6, e0057121	5	1
11	Association of HLA genotypes, AB0 blood type and chemokine receptor 5 mutant CD195 with the clinical course of COVID-19. <i>European Journal of Medical Research</i> , <b>2021</b> , 26, 107	4.8	3
10	Safety and Efficacy of Convalescent Plasma in COVID-19: An Overview of Systematic Reviews. <i>Diagnostics</i> , <b>2021</b> , 11,	3.8	6
9	Convalescent Plasma Therapy for COVID-19: A Graphical Mosaic of the Worldwide Evidence. <i>SSRN Electronic Journal</i> ,	1	1
8	Current treatment strategies for COVID-19 (Review). <i>Molecular Medicine Reports</i> , <b>2021</b> , 24,	2.9	2
7	Association of Convalescent Plasma Treatment With Clinical Status in Patients Hospitalized With COVID-19: A Meta-analysis <i>JAMA Network Open</i> , <b>2022</b> , 5, e2147331	10.4	4
6	Access to and safety of COVID-19 convalescent plasma in the United States Expanded Access Program: A national registry study <i>PLoS Medicine</i> , <b>2021</b> , 18, e1003872	11.6	5
5	Convalescent Plasma for Preventing Critical Illness in COVID-19: a Phase 2 Trial and Immune Profile <i>Microbiology Spectrum</i> , <b>2022</b> , 10, e0256021	8.9	0
4	The Quality of Anti-SARS-CoV-2 T Cell Responses Predicts the Neutralizing Antibody Titer in Convalescent Plasma Donors <i>Frontiers in Public Health</i> , <b>2022</b> , 10, 816848	6	0
3	Neutralizing antibody responses over time in demographically and clinically diverse individuals recovered from SARS-CoV-2 infection in the United States and Peru: A cohort study. <i>PLoS Medicine</i> , <b>2021</b> , 18, e1003868	11.6	2
2	Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients An Open-Label Phase II Clinical Trial. <b>2022</b> , 12, 1565		O
1	Home and Out-of-Hospital Therapy with COVID-19 Convalescent Plasma in Europe. <b>2022</b> , 12, 1704		0